Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide

Pharmacological Reports

Volumn 62, Issue 5, 2010, Pages 956-965

  Łabuzek, Krzysztof ^a   Suchy, Dariusz ^a   Gabryel, Bozena ^a   Bielecka, Anna ^a   Liber, Sebastian ^a   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Brain; Cerebrospinal fluid; HPLC; Lipopolysaccharide; Metformin; Plasma; Rat

Indexed keywords

LIPOPOLYSACCHARIDE; METFORMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; FRONTAL CORTEX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIPPOCAMPUS; HYPOPHYSIS; HYPOTHALAMUS; INFLAMMATION; MALE; NONHUMAN; OLFACTORY BULB; RAT; SINGLE DRUG DOSE;

EID: 79551493930     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70357-1     Document Type: Article

References (31)

1. Aburuz S, Millership J, McElnay J: The development and validation of liquid chromatography method for the simultaneous determination of metformin and glipizide, gliclazide, glibenclamide or glimperide in plasma. J Chromatogr B Analyt Technol Biomed Life Sc, 2005, 817, 277-286.
2. Beckmann R: Biguanide (Experimenteller Teil). In: Handbook of Experimental Pharmacology, Ed. Maske H, Springer-Verlag, Berlin, 1971, 29, 439-596.
3. Beckner ME, Gobbel GT, Abounader R, Burovic F, Agostino NR, Laterra J, Pollack IF: Glycolytic glioma cells with active glycogen synthase are sensitive to PTEN and inhibitors of PI3K and gluconeogenesis. Lab Invest, 2005, 85, 1457-1470.
4. Bickel U, Grave B, Kang YS, del Rey A, Voigt K: No increase in blood-brain barrier permeability after intraperitoneal injection of endotoxin in the rat. J Neuroimmunol, 1998, 85, 131-136.
5. Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP: Metformin inhibits adenosine 5′-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology, 2007, 148, 507-511.
6. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, Thompson RC et al.: Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription. Proc Natl Acad Sci USA, 2009, 106, 3907-3912.
7. Cho YK, Choi YH, Kim SH, Lee MG: Effects of Escherichia coli lipopolysaccharide on the metformin pharmacokinetics in rats. Xenobiotica, 2009, 39, 946-954.
8. Choi MK, Song IS: Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet, 2008, 23, 243-253.
9. El-Mir MY, Detaille D, R-Villanueva G, Delgado-Esteban M, Guigas B, Attia S, Fontaine E et al.: Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J Mol Neurosci, 2008, 34, 77-87.
10. Hale TW, Kristensen JH, Hackett LP, Kohan R, Ilett KF: Transfer of metformin into human milk. Diabetologia, 2002,45,1509-1514.
11. Isoda K, Young JL, Zirlik A, MacFarlane LA, Tsuboi N, Gerdes N, Schönbeck U, Libby P: Metformin inhibits proinflammatory responses and nuclear factor-γB in human vascular wall cells. Arterioscler Thromb Vasc Biol, 2006,26,611-617.
12. Iwasaki Y, Nishiyama M, Taguchi T, Kambayashi M, Asai M, Yoshida M, Nigawara T, Hashimoto K: Activation of AMP-activated protein kinase stimulates proopiomelanocortin gene transcription in AtT20 corticotroph cells. Am J Physiol Endocrinol Metab, 2007,292, 899-905.
13. Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, Huh JY, Moon KH: Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes, 2006, 55, 716-724.
14. Kola B: Role of AMP-activated protein kinase in the control of appetite. J Neuroendocrinol, 2008, 20, 942-951.
15. Lage R, Diéguez C, Vidal-Puig A, López M: AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med, 2008, 14, 539-549.
16. Li L, Mamputu JC, Wiernsperger N, Renier G: Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes, 2005, 54, 2227-2234.
17. Lutz TA, Estermann A, Haag S, Scharrer E: Depolarization of the liver cell membrane by metformin. Biochim Biophys Acta, 2001, 1513, 176-184.
18. Labuzek K, Liber S, Gabryel B, Adamczyk J, Okopieñ B: Metformin increases phagocytosis and acidifies lysosomal/endosomal compartments in AMPK-dependent manner in rat primary microglia. Naunyn Schmiedebergs Arch Pharmacol, 2010, 381, 171-186.
19. Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR: Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett, 2007,411,98-103.
20. Mamputu JC, Wiernsperger NF, Renier G: Antiatherogenic properties of metformin: the experimental evidence. Diabetes Metab, 2003, 29, 6S71-6S76.
21. Nath N, Khan M, Paintlia MK, Hoda MN, Giri S: Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J Immunol, 2009, 182, 8005-8014.
22. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates, 6th edn., Elsevier, Amsterdam, 2007.
23. Quan N, Stern EL, Whiteside MB, Herkenham M: Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat. J Neuroimmunol, 1999, 93, 72-80.
24. Richter EA, Ruderman NB: AMPK and the biochemistry of exercise: implications for human health and disease. Biochem J, 2009, 418, 261-275.
25. Saeedi R, Parsons HL, Wambolt RB, Paulson K, Sharma V, Dyck JR, Brownsey RW, Allard MF: Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol, 2008, 294, 2497-2506.
26. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF: Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol, 1981, 12, 235-246.
27. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle, 2009, 8, 88-96.
28. Wilcock C, Bailey CJ: Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica, 1994, 24, 49-57.
29. Wilcock C, Wyre ND, Bailey CJ: Subcellular distribution of metformin in rat liver. J Pharm Pharmacol, 1991, 43, 442-444.
30. Weill-Engerer S, David JP, Sazdovitch V, Liere P, Eychenne B, Pianos A, Schumacher M et al.: Neurosteroid quantification in human brain regions: comparison between Alzheimer's and nondemented patients. J Clin Endocrinol Metab, 2002, 87, 5138-5143.
31. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001, 108, 1167-1174.